Health Robotics along with the Japan- based Tosho was successful in winning the public tender purchasing process, for its cancer therapy robot CytoCare, and the tender was sponsored by the Oxaliplatin Fund at the Cancer Center of Nagoya City University Hospital .
The Nagoya City University Hospital is an established center for Oncology in the Asia-Pacific region. It has the credit for introducing Oxaliplatin, which is a drug used in the treatment of cancer through chemotherapy. Oxaliplatin has platinum as the base and is usually combined with fluorouracil and leucovorin for chemotherapy of colorectal cancer. The Oxaliplatin Fund is a non-profit fund which has initiated the tender for the benefit of Nagoya City University Hospital. Tosho will be installing the CytoCare at the Kameda Hospital and National Cancer Center in Tokyo.
CytoCare is the first robot which exhibited the capability of administering safe and sterile drugs for chemotherapy. It has been installed at more than 65 centers across the world. CytoCare has an established reputation of being able to adapt to any kind of workflow at pharmacies and different I.V consumables across the world. It is still the only robot that is able to successfully deliver live patient doses during chemotherapy. Health Robotics has also revealed its plans of displaying the capabilities of i.v. STATION ONCO robot at the 46th Midyear Clinical Meeting and Exhibition of the American Society of Health System Pharmacists (ASHP). The event is scheduled to be held between 4 and 8 December at New Orleans. Another revolutionary robotic station from Health Robotics, mAbs will be launched on 9 November at a world press meet.